Compare Dr. Reddys with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs PFIZER - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB PFIZER DR. REDDYS LAB/
PFIZER
 
P/E (TTM) x 21.6 33.0 65.4% View Chart
P/BV x 3.2 5.5 58.4% View Chart
Dividend Yield % 0.7 0.6 118.7%  

Financials

 DR. REDDYS LAB   PFIZER
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
PFIZER
Mar-18
DR. REDDYS LAB/
PFIZER
5-Yr Chart
Click to enlarge
High Rs2,8752,365 121.6%   
Low Rs1,8881,625 116.2%   
Sales per share (Unadj.) Rs930.2430.3 216.2%  
Earnings per share (Unadj.) Rs117.478.7 149.2%  
Cash flow per share (Unadj.) Rs185.893.2 199.3%  
Dividends per share (Unadj.) Rs20.0020.00 100.0%  
Dividend yield (eoy) %0.81.0 83.8%  
Book value per share (Unadj.) Rs844.4586.5 144.0%  
Shares outstanding (eoy) m166.0745.75 363.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.64.6 55.2%   
Avg P/E ratio x20.325.3 80.0%  
P/CF ratio (eoy) x12.821.4 59.9%  
Price / Book Value ratio x2.83.4 82.9%  
Dividend payout %17.025.4 67.0%   
Avg Mkt Cap Rs m395,49691,271 433.3%   
No. of employees `00022.02.6 835.2%   
Total wages/salary Rs m33,5623,143 1,067.9%   
Avg. sales/employee Rs Th7,032.87,484.8 94.0%   
Avg. wages/employee Rs Th1,527.91,195.0 127.9%   
Avg. net profit/employee Rs Th887.71,369.1 64.8%   
INCOME DATA
Net Sales Rs m154,48219,685 784.8%  
Other income Rs m3,3751,143 295.3%   
Total revenues Rs m157,85720,828 757.9%   
Gross profit Rs m31,7825,003 635.3%  
Depreciation Rs m11,348663 1,712.9%   
Interest Rs m8894 21,166.7%   
Profit before tax Rs m22,9205,479 418.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,8581,878 205.4%   
Profit after tax Rs m19,5003,601 541.6%  
Gross profit margin %20.625.4 81.0%  
Effective tax rate %16.834.3 49.1%   
Net profit margin %12.618.3 69.0%  
BALANCE SHEET DATA
Current assets Rs m111,10124,167 459.7%   
Current liabilities Rs m58,9739,544 617.9%   
Net working cap to sales %33.774.3 45.4%  
Current ratio x1.92.5 74.4%  
Inventory Days Days7955 144.0%  
Debtors Days Days9429 328.2%  
Net fixed assets Rs m101,2459,514 1,064.2%   
Share capital Rs m830458 181.4%   
"Free" reserves Rs m139,40626,375 528.6%   
Net worth Rs m140,23626,832 522.6%   
Long term debt Rs m22,00025 88,000.0%   
Total assets Rs m224,65636,900 608.8%  
Interest coverage x26.81,305.5 2.1%   
Debt to equity ratio x0.20 16,837.4%  
Sales to assets ratio x0.70.5 128.9%   
Return on assets %9.19.8 92.9%  
Return on equity %13.913.4 103.6%  
Return on capital %14.920.4 73.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,67322 395,861.6%   
Fx outflow Rs m19,1041,489 1,283.3%   
Net fx Rs m69,569-1,466 -4,744.5%   
CASH FLOW
From Operations Rs m28,7043,318 865.1%  
From Investments Rs m-7,727-2,383 324.3%  
From Financial Activity Rs m-21,326-1,104 1,932.6%  
Net Cashflow Rs m-314-169 186.4%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 5.4 7.5 72.0%  
FIIs % 35.3 4.9 720.4%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 23.7 64.6%  
Shareholders   75,885 85,207 89.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   GLENMARK PHARMA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  DIVIS LABORATORIES  UNICHEM LAB  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 19, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - TTK HEALTHCARE COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS